Quercetin: Difference between revisions
→Pharmacological Properties
| Line 201: | Line 201: | ||
===Quercetin Phytosome=== | ===Quercetin Phytosome=== | ||
[[File:Pharmacokinetic profile of quercetin.png|thumb|[[Pharmacokinetic]] profile of standard quercetin and quercetin phytosome in the clinical study. The plasma concentrations of quercetin obtained after single oral administration of the unformulated quercetin at 500 mg/tablet and after single oral administration of its corresponding lecithin formulation, Quercetin Phytosome, at a dose of either 500 or 250 mg are shown. <ref name=":0">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418071/</ref>]] | [[File:Pharmacokinetic profile of quercetin.png|thumb|[[Pharmacokinetic]] profile of standard quercetin and quercetin phytosome in the clinical study. The plasma concentrations of quercetin obtained after single oral administration of the unformulated quercetin at 500 mg/tablet and after single oral administration of its corresponding lecithin formulation, Quercetin Phytosome, at a dose of either 500 or 250 mg are shown. <ref name=":0">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418071/</ref>]] | ||
Quercetin Phytosome is a formulation where quercetin is bound to phospholipids, typically derived from sunflower or soy lecithin, to enhance its bioavailability and absorption. The relevant clinical study used Quercetin Phytosome (QUERCEFIT™) consisting of quercetin and sunflower lecithin in a 1:1 weight ratio along with about a fifth part of food-grade excipients that are added to improve the physical state of the product and to standardize it to an HPLC-measured total quercetin content of about 40%. In the clinical study, a ~20-fold increase in bioavailability was measured compared to standard quercetin with equal doses. <ref name=":0" /> | Quercetin Phytosome is a formulation where quercetin is bound to phospholipids, typically derived from sunflower or soy lecithin, to enhance its bioavailability and absorption. The relevant clinical study used Quercetin Phytosome (QUERCEFIT™) consisting of quercetin and sunflower lecithin in a 1:1 weight ratio along with about a fifth part of food-grade excipients that are added to improve the physical state of the product and to standardize it to an HPLC-measured total quercetin content of about 40%. In the clinical study, a ~20-fold increase in bioavailability was measured compared to standard quercetin with equal doses. <ref name=":0" />{| class="wikitable" | ||
{| class="wikitable" | |||
|+[[Pharmacokinetic]] parameters (noncompartmental model) <ref name=":0" /> | |+[[Pharmacokinetic]] parameters (noncompartmental model) <ref name=":0" /> | ||
! | ! | ||
| Line 210: | Line 209: | ||
|- | |- | ||
|[[AUClast|AUC<sub>last</sub>]] (min × ng/ml) | |[[AUClast|AUC<sub>last</sub>]] (min × ng/ml) | ||
| 4774.93 ± 1190.61 | |||
| 96,163.87 ± 9291.31 | |||
| 50,401.53 ± 6418.22 | |||
|- | |- | ||
| colspan="1" rowspan="1" |[[Cmax|C<sub>max</sub>]] (ng/ml) | | colspan="1" rowspan="1" |[[Cmax|C<sub>max</sub>]] (ng/ml) | ||
| 10.93 ± 2.22 | |||
| 223.10 ± 16.32 | |||
| 126.35 ± 14.79* | |||
|- | |- | ||
| colspan="1" rowspan="1" |[[Time to Maximum Concentration (Tmax)|T<sub>max</sub>]] (min) | | colspan="1" rowspan="1" |[[Time to Maximum Concentration (Tmax)|T<sub>max</sub>]] (min) | ||
| 290.00 ± 31.19 | |||
| 202.50 ± 35.97 | |||
| 228.75 ± 36.61 | |||
|- | |- | ||
| colspan="1" rowspan="1" |''t''<sub>1/2</sub> (min) | | colspan="1" rowspan="1" |''t''<sub>1/2</sub> (min) | ||
| 375.63 ± 75.51 | |||
| 226.84 ± 8.13 | |||
| 201.63 ± 13.18 | |||
|- | |- | ||
| MRT last (min) | |||
| 410.41 ± 24.24 | |||
| 372.94 ± 20.12 | |||
| 386.29 ± 21.04 | |||
|} | |} | ||
Quercetin Phytosome overcomes the low bioavailability hurdle of quercetin and should help to fulfill the great health benefit potential of this flavonoid in the diet and as food supplements. | Quercetin Phytosome overcomes the low bioavailability hurdle of quercetin and should help to fulfill the great health benefit potential of this flavonoid in the diet and as food supplements. | ||
| Line 239: | Line 239: | ||
'''Quercetin LipoMicel''' is a novel formulation from Natural Factors designed to enhance the bioavailability of quercetin. LipoMicel encapsulates quercetin molecules within micelles, tiny spherical structures formed from natural, non-ionic surfactants. These micelles facilitate the solubilization of quercetin, allowing it to be more readily absorbed in the gastrointestinal tract. In a study sponsored by Natural Factors, the bioavailability of Standard Quercetin, Quercetin Phytosome and Quercetin LipoMicel was compared. Thereby, Quercetin Phytosome had a slightly higher relative bioavailability (AUC) than for Quercetin LipoMicel, but longer steady state levels of quercetin were provided by LipoMicel. | '''Quercetin LipoMicel''' is a novel formulation from Natural Factors designed to enhance the bioavailability of quercetin. LipoMicel encapsulates quercetin molecules within micelles, tiny spherical structures formed from natural, non-ionic surfactants. These micelles facilitate the solubilization of quercetin, allowing it to be more readily absorbed in the gastrointestinal tract. In a study sponsored by Natural Factors, the bioavailability of Standard Quercetin, Quercetin Phytosome and Quercetin LipoMicel was compared. Thereby, Quercetin Phytosome had a slightly higher relative bioavailability (AUC) than for Quercetin LipoMicel, but longer steady state levels of quercetin were provided by LipoMicel. | ||
{| class="wikitable" | |||
|+[[Pharmacokinetic]] parameters (noncompartmental model) <ref name=":0" /> | |||
! | |||
!Quercetin 500 mg | |||
!Quercetin Phytosome 500 mg | |||
!Quercetin Phytosome 250 mg | |||
|- | |||
|[[AUClast|AUC<sub>last</sub>]] (min × ng/ml) | |||
| 4774.93 ± 1190.61 | |||
| 96,163.87 ± 9291.31 | |||
| 50,401.53 ± 6418.22 | |||
|- | |||
| colspan="1" rowspan="1" |[[Cmax|C<sub>max</sub>]] (ng/ml) | |||
| 10.93 ± 2.22 | |||
| 223.10 ± 16.32 | |||
| 126.35 ± 14.79* | |||
|- | |||
| colspan="1" rowspan="1" |[[Time to Maximum Concentration (Tmax)|T<sub>max</sub>]] (min) | |||
| 290.00 ± 31.19 | |||
| 202.50 ± 35.97 | |||
| 228.75 ± 36.61 | |||
|- | |||
| colspan="1" rowspan="1" |''t''<sub>1/2</sub> (min) | |||
| 375.63 ± 75.51 | |||
| 226.84 ± 8.13 | |||
| 201.63 ± 13.18 | |||
|- | |||
| MRT last (min) | |||
| 410.41 ± 24.24 | |||
| 372.94 ± 20.12 | |||
| 386.29 ± 21.04 | |||
|} | |||
==Clinical Applications and Effects on Longevity== | ==Clinical Applications and Effects on Longevity== | ||